ConforMIS Inc (NASDAQ:CFMS) insider David Cerveny sold 5,478 shares of ConforMIS stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $12,435.06. Following the sale, the insider now owns 152,073 shares in the company, valued at approximately $345,205.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Cerveny also recently made the following trade(s):
- On Wednesday, November 15th, David Cerveny sold 16,392 shares of ConforMIS stock. The stock was sold at an average price of $3.17, for a total transaction of $51,962.64.
ConforMIS Inc (NASDAQ CFMS) opened at $2.61 on Friday. ConforMIS Inc has a 1-year low of $2.21 and a 1-year high of $8.61. The stock has a market cap of $118.21 and a price-to-earnings ratio of -1.95. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52.
ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. The company had revenue of $18.40 million during the quarter, compared to the consensus estimate of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.31) earnings per share. sell-side analysts expect that ConforMIS Inc will post -1.27 EPS for the current year.
A number of hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in ConforMIS by 2.0% in the second quarter. Wells Fargo & Company MN now owns 55,021 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 1,091 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in ConforMIS by 21.4% in the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 6,535 shares during the period. Rhumbline Advisers lifted its holdings in ConforMIS by 21.8% in the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 8,017 shares during the period. State Street Corp lifted its holdings in ConforMIS by 1.5% in the second quarter. State Street Corp now owns 594,583 shares of the medical instruments supplier’s stock worth $2,550,000 after purchasing an additional 8,693 shares during the period. Finally, Alliancebernstein L.P. raised its position in ConforMIS by 31.1% in the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 9,500 shares in the last quarter. 35.57% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on the stock. BTIG Research restated a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. JPMorgan Chase & Co. lowered shares of ConforMIS from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Finally, Zacks Investment Research lowered shares of ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $5.54.
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.